| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-167256.txt","as_of":"2026-04-22T03:03:32.063787+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-167256.txt","company":"SPRUCE BIOSCIENCES, INC.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-167256.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_9da7a9446b4c5525","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-167256.txt","content_type":"text/plain","enriched_at":"2026-04-22T03:25:14.360045+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"424B5","final_url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-167256.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-167256.txt","source_event_id":"evt_efcc2edb15db","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"424B5","fp":"d85b8056db67e9f5","kind":"sec_filing","published_at":"20260421","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.86,"dates_mentioned":["2026-04-21","2026-04-20","2026-04-22","2026-04-20 (prospectus supplement dated)","2025-10-29"],"entities":[{"asset_class":"equity","name":"Spruce Biosciences, Inc.","relevance":"high","symbol":"SPRB","type":"issuer"},{"asset_class":"market","name":"Nasdaq Capital Market","relevance":"medium","symbol":"","type":"exchange"},{"asset_class":"other","name":"Leerink Partners","relevance":"medium","symbol":"","type":"underwriter"},{"asset_class":"other","name":"Guggenheim Securities","relevance":"medium","symbol":"","type":"underwriter"},{"asset_class":"other","name":"Oppenheimer & Co.","relevance":"medium","symbol":"","type":"underwriter"},{"asset_class":"other","name":"Jones","relevance":"low","symbol":"","type":"co-manager"},{"asset_class":"other","name":"Craig-Hallum","relevance":"low","symbol":"","type":"co-manager"}],"event_type":"listing","information_gaps":["What the public offering price per share is (the text references it but does not state the numeric value).","Whether the 1,150,000 shares are sold at the same public offering price as referenced for the pre-funded warrants (implied but not explicitly quantified in the provided text).","What changed vs prior known state is not provided in the signal beyond the fact that this 424B5 was filed; no prior filing details are included to compare deltas.","Any additional risk factors or underwriting expense reimbursement details are referenced but not included in the provided excerpt."],"key_facts":["Form 424B5 filed pursuant to Rule 424(b)(5) for registration statement No. 333-291152.","Offering includes 1,150,000 shares of common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase 50,000 shares of common stock.","Pre-funded warrant purchase price equals the public share price minus $0.01; pre-funded warrant exercise price is $0.01 per share.","Shares issuable upon exercise of pre-funded warrants are also being offered.","No established public trading market for the pre-funded warrants; the issuer does not expect a market to develop and does not intend to apply for listing of the pre-funded warrants.","Last reported sale price of common stock on Nasdaq Capital Market on April 20, 2026 was $69.89 per share.","Delivery of shares and pre-funded warrants expected on or about April 22, 2026.","Underwriters have a 30-day option to purchase up to an additional 180,000 shares at the public offering price, less underwriting discounts and commissions.","If the option is exercised in full, underwriting discounts/commissions payable by the issuer total $4,140,000 and total proceeds to the issuer before expenses total $64,859,500."],"numeric_claims":[{"label":"Common shares offered","value":"1,150,000"},{"label":"Pre-funded warrants shares underlying","value":"50,000"},{"label":"Pre-funded warrant exercise price ($/share)","value":"0.01"},{"label":"Pre-funded warrant purchase price adjustment ($)","value":"0.01 less than public share price"},{"label":"Last reported sale price (Apr 20, 2026)","value":"69.89"},{"label":"Delivery expected","value":"on or about April 22, 2026"},{"label":"Underwriter option period (days)","value":"30"},{"label":"Underwriter option additional shares","value":"180,000"},{"label":"Underwriting discounts/commissions if option exercised in full","value":"4,140,000"},{"label":"Total proceeds before expenses if option exercised in full","value":"64,859,500"}],"primary_claim":"SPRB filed a Form 424B5 prospectus supplement for an offering of 1,150,000 shares of common stock and pre-funded warrants (exercise price $0.01) to purchase 50,000 shares, with delivery expected on or about April 22, 2026.","relevance_score":0.72,"sentiment":"neutral","source_quality":"high","summary":"Spruce Biosciences, Inc. filed a Form 424B5 prospectus supplement for an offering of 1,150,000 shares of common stock and pre-funded warrants to purchase 50,000 shares. The filing states the pre-funded warrant exercise price is $0.01 and provides offering timing and underwriter option details.","topics":["SEC filing","prospectus supplement","common stock offering","pre-funded warrants","underwriting","Nasdaq listing","smaller reporting company"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 424B5 \u00b7 SPRUCE BIOSCIENCES, INC. \u00b7 Filed 20260421","ticker":"SPRB","tickers":["SPRB"],"title":"SPRB filed 424B5","url":"https://www.sec.gov/Archives/edgar/data/1683553/0001193125-26-167256.txt"}... |